Skip to content
  • Sunday, 26 July 2026
  • 2:58 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Pharmaceutical R&D

Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia

Teuku Ryan Jun 27, 2026 0

Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…

Read More
Pharmaceutical R&D

Pharma Manufacturing Facility Sales to Outsourcers Signal Growing Industry Demand for Strategic Flexibility

Teuku Ryan May 12, 2026 0

A notable surge in the acquisition of pharmaceutical manufacturing facilities by contract development and manufacturing organizations (CDMOs) has illuminated a…

Read More
Laboratory Automation & Robotics

TrumpRx.gov: A Federal Portal’s Ambitions and the Intensifying Scrutiny of Direct-to-Consumer Drug Sales

Lana Keisha Mar 31, 2026 0

As of early February, TrumpRx.gov presents a starkly minimalist facade: a stylized Oval Office portrait of the president accompanied by…

Read More
Laboratory Automation & Robotics

TrumpRx.gov: A Federal Portal Faces Scrutiny Amidst Concerns Over Direct-to-Consumer Drug Sales and Patient Safety.

Lana Keisha Mar 23, 2026 0

As of early February, the federal portal TrumpRx.gov remains in a nascent state, displaying only a stylized Oval Office portrait…

Read More
Decoding the Bone Marrow Microenvironment: How Chronic Inflammation Drives Early Blood Disorders and Clonal EvolutionHow AI Agents Will Transform Data Science Work in 2026TWiV 1291: A Foot in the Door for CytomegalovirusScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ